How do specific commensal gut bacteria or their metabolites (e.g., SCFAs like butyrate, Bacteroides fragilis PSA) differentially regulate the expression and signaling pathways of IL-6, TNF-α, and IL-10 in systemic circulation, and can this be harnessed therapeutically?
Local gut effects translate systemically through:
| Approach | Potential | Challenges |
|---|---|---|
| Probiotics | SCFA-producers (Faecalibacterium), PSA+ strains | Strain specificity, engraftment variability, safety in immunocompromised |
| Prebiotics | Fibers that boost SCFA producers (inulin, resistant starch) | Responder variability, GI side effects |
| Postbiotics | Direct metabolite delivery (butyrate, PSA) | Delivery optimization, pharmacokinetics, dosing |
| Synbiotics | Combined pro/prebiotic synergy | Optimal pairing determination |
| FMT | Microbiome restoration in dysbiosis | Standardization, safety regulations |
Commensal bacteria and metabolites differentially regulate cytokines through HDAC inhibition (SCFAs), GPCR signaling (SCFAs), and TLR2 pathways (PSA). These mechanisms converge on NF-κB regulation, immune cell differentiation, and barrier protection, resulting in reduced IL-6/TNF-α and elevated IL-10 systemically.
Therapeutic harnessing shows promise but requires solutions for individual variability, delivery optimization, and demonstration of clinical efficacy through rigorous trials.